Relapsed/Refractory Hodgkin Lymphoma

Pediatric Oncology Exploring the Efficacy and Safety of Pembrolizumab in Relapsed and Refractory Pediatric Hodgkin’s Lymphoma: Insights from the KHCC Experience
Faiha Bazzeh • Esraa Badarin • Iyad Sultan
doi.org/10.69690/ODMJ-018-0425-1982
Pediatric Oncology Pediatric relapsed and refractory classical Hodgkin’s lymphoma: Treatment approaches
Timur T. Valiev • Tsaplina N.S. • Kozlov A.V. • Natalia Batmanova • Kirill Kirgizov • Zubarovskaya L.S. • Svetlana Varfolomeeva
doi.org/https://doi.org/10.69690/ODMJ-018-0425-1802
Pediatric Oncology Immune Checkpoint Inhibitors Treatment in Children with Relapsed/Refractory Hodgkin Lymphoma
Elizaveta Tuzova • Dmitrii Evstratov • Alexey Pshonkin • Maya Korsantya • Ivan Fisyn • Dmitry Litvinov • Natalia Miakova
doi.org/10.69690/ODMJ-018-0425-1121